Actinium Pharmaceuticals (NYSEAM:ATNM) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ATNM Stoklara Genel Bakış

ATNM temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Trading at 95.2% below our estimate of its fair value

Revenue is forecast to grow 61.33% per year

Risk Analizi

Makes less than USD$1m in revenue ($81K)

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 daha fazla risk

Actinium Pharmaceuticals, Inc. Rakipler

Homology Medicines

NasdaqGS:FIXX

US$54.3m

MediciNova

NasdaqGM:MNOV

US$103.0m

Entera Bio

NasdaqCM:ENTX

US$69.0m

RAPT Therapeutics

NasdaqGM:RAPT

US$70.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Actinium Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.82
52 Haftanın En Yüksek Seviyesi	US$10.24
52 Haftanın En Düşük Seviyesi	US$1.33
Beta	0.15
11 Aylık Değişim	-8.54%
3 Aylık Değişim	-75.00%
1 Yıllık Değişim	-68.29%
33 Yıllık Değişim	-78.18%
5 Yıllık Değişim	-69.82%
Halka arzdan bu yana değişim	-97.98%

Son Haberler & Güncellemeler

Recent updates

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Dec 28

Hissedar Getirileri

	ATNM	US Biotechs	US Pazar
7D	0.6%	-0.2%	-0.4%
1Y	-68.3%	22.1%	34.1%

Getiri vs. Endüstri: ATNM underperformed the US Biotechs industry which returned 21.7% over the past year.

Getiri vs Piyasa: ATNM underperformed the US Market which returned 33.4% over the past year.

Fiyat Oynaklığı

Is ATNM's price volatile compared to industry and market?
ATNM volatility
ATNM Average Weekly Movement	21.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ATNM's share price has been volatile over the past 3 months.

Zaman İçindeki Volatilite: ATNM's weekly volatility has increased from 15% to 22% over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	49	Sandesh Seth	www.actiniumpharma.com

Actinium Pharmaceuticals, Inc. mevcut onkoloji tedavilerinde başarısız olan kişiler için sonuçları iyileştirmeyi amaçlayan antikor radyasyon konjugatları ve diğer hedefli radyoterapiler geliştirmektedir. Iomab-B, nükseden ve refrakter akut miyeloid lösemi (r/r AML) hastalarında kemik iliği nakli öncesinde bir indüksiyon ve kondisyonlama ajanıdır. Şirket, r/r AML hastalarında potansiyel aktivite gösteren terapötik bir ajan olan ürün adayı Actimab-A için geliştirmesini ilerletmeye odaklanmaktadır.

Actinium Pharmaceuticals, Inc. Temel Bilgiler Özeti

Actinium Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ATNM temel i̇stati̇sti̇kler
Piyasa değeri	US$58.57m
Kazançlar(TTM)	-US$42.62m
Gelir(TTM)	US$81.00k

700.0x

P/S Oranı

-1.3x

F/K Oranı

ATNM aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ATNM gelir tablosu (TTM)
Gelir	US$81.00k
Gelir Maliyeti	US$0
Brüt Kâr	US$81.00k
Diğer Giderler	US$42.70m
Kazançlar	-US$42.62m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.37
Brüt Marj	100.00%
Net Kâr Marjı	-52,620.99%
Borç/Özkaynak Oranı	0%

ATNM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ATNM Stoklara Genel Bakış

Ödüller

Risk Analizi

Actinium Pharmaceuticals, Inc. Rakipler

NasdaqGS:FIXX

US$54.3m

NasdaqGM:MNOV

US$103.0m

NasdaqCM:ENTX

US$69.0m

NasdaqGM:RAPT

US$70.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Actinium Pharmaceuticals, Inc. Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Recent updates

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Actinium Pharmaceuticals, Inc. Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial

Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy

Price target increased by 8.4% to US$25.36

Price target increased by 32% to US$23.40

Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Consensus revenue estimates fall by 85%

Price target decreased by 25% to US$18.61

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

Price target decreased by 13% to US$24.78

Consensus EPS estimates fall by 10%

Price target decreased by 8.9% to US$27.41

Consensus revenue estimates decrease by 52%, EPS upgraded

Consensus revenue estimates increase by 13%

Price target increased by 15% to US$32.62

Actinium Pharmaceuticals, Inc. to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings

Forecast to breakeven in 2025

Actinium Highlights Survival Data in Relapsed/Refractory Aml Patients with Prior Venetoclax Treatment And/Or with A Tp53 Mutation from the Actimab-A Clag-M Combination Trial Oral Presentation At Ash

Consensus revenue estimates fall by 16%

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Consensus forecasts updated

Forecast to breakeven in 2024

Price target increased to US$28.43

Insufficient new directors

Actinium Pharmaceuticals, Inc. Provides Update on Iomab-B and the Pivotal Phase 3 Trial

Price target increased to US$27.23

Actinium Pharmaceuticals, Inc. Announces Positive Top-Line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. Announces Executive Changes

Actinium Pharmaceuticals, Inc. Announces Executive Appointments

Actinium Pharmaceuticals, Inc. Provides Topline Results for the Pivotal Phase 3 Sierra Trial for Iomab-B

No longer forecast to breakeven

Price target decreased to US$24.04

Consensus revenue estimates fall by 22%

Consensus forecasts updated

Consensus revenue estimates increase by 193%

Price target decreased to US$26.71

Insufficient new directors

Actinium Pharmaceuticals, Inc. Highlights Data from Full Patient Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B Was Presented in an Oral Presentation At the Upcoming Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

Actinium Pharmaceuticals, Inc. Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

Forecast to breakeven in 2024

Forecast to breakeven in 2023

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Positive Data from Fully Enrolled Pivotal Phase 3 SIERRA Trial of Iomab-B Presents at 63rd American Society of Hematology Annual Meeting and Exposition

Forecast to breakeven in 2023

Chief Medical Officer Mark Berger has left the company

Chief Medical Officer Mark Berger has left the company

Actinium Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B